SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $422,822 | -48.6% | 29,120 | -25.9% | 0.00% | -66.7% |
Q2 2023 | $822,193 | +47.1% | 39,283 | +20.6% | 0.00% | +50.0% |
Q2 2021 | $559,000 | -6.2% | 32,575 | +22.3% | 0.00% | -33.3% |
Q1 2021 | $596,000 | -70.6% | 26,639 | -70.8% | 0.00% | -80.0% |
Q4 2020 | $2,027,000 | +109.6% | 91,127 | +39.2% | 0.02% | +15.4% |
Q3 2020 | $967,000 | +221.3% | 65,484 | +222.4% | 0.01% | +160.0% |
Q2 2020 | $301,000 | -15.2% | 20,313 | -37.2% | 0.01% | -44.4% |
Q1 2020 | $355,000 | +327.7% | 32,356 | +73.9% | 0.01% | +800.0% |
Q4 2018 | $83,000 | -16.2% | 18,601 | +51.3% | 0.00% | 0.0% |
Q3 2018 | $99,000 | +11.2% | 12,298 | +20.4% | 0.00% | -50.0% |
Q4 2017 | $89,000 | – | 10,216 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |